Gilead与Teva公司解决VIREAD的专利诉讼案

StephenW

Gilead to resolve Viread patent litigation case with Teva
Published on February 20, 2013 at 12:50 AM ·



Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread® (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

"We believe strongly in the validity of our intellectual property," said John Milligan, PhD, Gilead's President and Chief Operating Officer. "This settlement, however, removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation."

The trial in this litigation, which was scheduled to begin on Wednesday, February 20 in the District Court for the Southern District of New York, has been adjourned pending completion of activities necessary to finalize the settlement.

Source: Gilead Sciences

Gilead Sciences公司（纳斯达克股票代码：GILD）今天宣布，Gilead公司和Teva制药公司已经在原则上达成了协议，解决现有的专利诉讼有关的专利保护VIREAD的®（富马酸替诺福韦），用于治疗HIV感染和慢性B型肝炎根据和解协议的条款，Teva公司将被允许到二零一七年12月15日推出的一个仿制版本VIREAD的。

“我们坚信我们的知识产权的有效性，Gilead公司的总裁兼首席营运官，说：”约翰·米利根博士。 “然而，这种结算方式，消除了一些不确定性，最大限度地减少进一步的分心，与此诉讼相关的人力和财力资源的投资。”

在本次诉讼的审判，这是定于2月20日（星期三）开始在纽约南部地区的区法院，已被延期，待完成必要的活动，以完成结算。

资料来源：吉利德科学公司（Gilead Sciences）

海上明月光

Teva制药公司仿制价格会便宜吗？

StephenW

回复 海上明月光 的帖子

我不知道。Teva是以色列公司.